Skip to content
lsd.com
CompletedPhase 1

Ketamine Trial for the Treatment of Depression

NCT02401139 · The University of New South Wales

Closed to entry
Status
Not accepting participants
Phase 1
Phase
10
Target enrolment
2
Study sites
Outside the US

What it is testing

Summary

This study is a Randomized Controlled Trial, investigating the safety and efficacy of administration of ketamine as a potential treatment for depression.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Montgomery Asberg Depression Rating Scale for Depression (MADRS)

    Measured over 4 weeks

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

16 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Individuals will be eligible for enrolment on the basis of: * major depressive disorder for at least three months duration * an inadequate response to at least 2 adequate antidepressants * MADRS ≥ 20 Patients will be excluded on the basis of: * History of psychosis * History of bipolar disorder * Any unstable medical or neurologic condition * Any Axis I disorder other than MDD judged to be primary presenting problem * Planned major changes to psychotropic medication * Significant risk of suicide * Planned or probable use of ECT * Age under 16 years, or 16-17 years without parental consent * Substance abuse or dependence in previous 6 months * Any history of abuse of ketamine or phencyclidine * Contraindication to the use of ketamine * Planned use of ketamine * Women of childbearing potential not taking reliable contraception * Likely non-compliance with trial treatment * Other condition judged by the treating clinician as likely to impact on the ability of the participant to complete the trial

Where

2 study sites

FacilityCityRegionCountry
Brain & Mind Research Institute (BMRI), University of SydneyCamperdownNew South WalesAustralia
Black Dog Institute, University of New South WalesSydneyNew South WalesAustralia

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT02401139 on ClinicalTrials.gov →

Last updated in the registry 2023-03-30. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits

Substance

All 2 trials from The University of New South Wales →